205 related articles for article (PubMed ID: 25700647)
1. [Myelodysplastic syndromes].
Thol F; Heuser M; Ganser A
Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract][Full Text] [Related]
3. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
Garcia-Manero G; Almeida A; Giagounidis A; Platzbecker U; Garcia R; Voso MT; Larsen SR; Valcarcel D; Silverman LR; Skikne B; Santini V
BMC Hematol; 2016; 16():12. PubMed ID: 27148452
[TBL] [Abstract][Full Text] [Related]
5. The search for better prognostic models in myelodysplastic syndromes.
Santos FP; Kantarjian H; Garcia-Manero G; Ravandi F
Curr Hematol Malig Rep; 2011 Mar; 6(1):13-21. PubMed ID: 21136214
[TBL] [Abstract][Full Text] [Related]
6. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
7. Treatment of low-risk myelodysplastic syndromes.
Santini V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):462-469. PubMed ID: 27913517
[TBL] [Abstract][Full Text] [Related]
8. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.
Schratz KE; DeZern AE
Hematol Oncol Clin North Am; 2020 Apr; 34(2):333-356. PubMed ID: 32089214
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A; Bernard E; Micol JB
Bull Cancer; 2023 Nov; 110(11):1129-1140. PubMed ID: 37391357
[TBL] [Abstract][Full Text] [Related]
10. [Current state of treatment for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2023; 64(9):988-997. PubMed ID: 37793875
[TBL] [Abstract][Full Text] [Related]
11. Getting personal with myelodysplastic syndromes: is now the right time?
Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome.
Kunimoto H; Miura A; Maeda A; Tsuchida N; Uchiyama Y; Kunishita Y; Nakajima Y; Takase-Minegishi K; Yoshimi R; Miyazaki T; Hagihara M; Yamazaki E; Kirino Y; Matsumoto N; Nakajima H
Int J Hematol; 2023 Oct; 118(4):494-502. PubMed ID: 37062784
[TBL] [Abstract][Full Text] [Related]
13. Improved Side Effect Profile of Alternate-Day Dosing of Lenalidomide.
Lawal RA; Banjoko O; Ndulue C; Adebeshin ST; Sharif A; Ighodaro OE; Olusoji R; Odusanya B; El-Hamdi NS
Cureus; 2024 Mar; 16(3):e55317. PubMed ID: 38559519
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Gurnari C; Pascale MR; Vitale A; Diral E; Tomelleri A; Galossi E; Falconi G; Bruno A; Crisafulli F; Frassi M; Cattaneo C; Bertoli D; Bernardi M; Condorelli A; Morsia E; Poloni A; Crisà E; Caravelli D; Triggianese P; Brussino L; Battipaglia G; Bindoli S; Sfriso P; Caroni F; Dragani M; Mallegni F; Pilo F; Firinu D; Curti A; Papayannidis C; Olivieri A; Kordasti S; Albano F; Pane F; Musto P; Bocchia M; Lugli E; Breccia M; Frigeni M; Dagna L; Greco R; Franceschini F; Campochiaro C; Cantarini L; Voso MT
Am J Hematol; 2024 Feb; 99(2):254-262. PubMed ID: 38108611
[TBL] [Abstract][Full Text] [Related]
15. The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score.
Silzle T; Blum S; Kasprzak A; Nachtkamp K; Rudelius M; Hildebrandt B; Götze KS; Gattermann N; Lauseker M; Germing U
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509235
[TBL] [Abstract][Full Text] [Related]
16. The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes.
Diamantidis M; Dimoudis S; Klonizakis P; Badekas K; Koutourli K; Haralambidou-Vranitsa S; Ioannidou-Papagiannaki E
Hippokratia; 2007 Oct; 11(4):178-82. PubMed ID: 19582190
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA; Gregorio C; Robin M; Gagelmann N; Gurnari C; Ball S; Caballero Berrocal JC; Lanino L; D'Amico S; Spreafico M; Maggioni G; Travaglino E; Sauta E; Meggendorfer M; Zhao LP; Campagna A; ; Savevski V; Santoro A; Al Ali N; Sallman D; Sole F; Garcia-Manero G; Germing U; Kroger N; Kordasti S; Santini V; Sanz G; Kern W; Platzbecker U; Diez-Campelo M; Maciejewski JP; Ades L; Fenaux P; Haferlach T; Zeidan AM; Castellani G; Komrokji R; Ieva F; Della Porta MG
J Clin Oncol; 2024 May; ():JCO2302175. PubMed ID: 38723212
[TBL] [Abstract][Full Text] [Related]
18. Lower-Risk Myelodysplastic Syndrome (MDS) Patients Exhibit Diminished Proteasome Proteolytic Activity and High Intracellular Reactive Oxygen Species (ROS) Levels.
Zafeiropoulou K; Kalampounias G; Alexis S; Androutsopoulou T; Katsoris P; Symeonidis A
Cureus; 2023 Dec; 15(12):e49843. PubMed ID: 38169896
[TBL] [Abstract][Full Text] [Related]
19. Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia.
Qiao W; Young E; Feng C; Liu S; Jin J; Noor L; Rojas Hernandez CM; Borthakur G; Gorlova O; Afshar-Kharghan V
Exp Hematol Oncol; 2022 Sep; 11(1):58. PubMed ID: 36114519
[TBL] [Abstract][Full Text] [Related]
20. Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.
Masala E; Valencia-Martinez A; Pillozzi S; Rondelli T; Brogi A; Sanna A; Gozzini A; Arcangeli A; Sbarba PD; Santini V
Oncotarget; 2018 Feb; 9(12):10561-10571. PubMed ID: 29535827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
